Transcatheter Aortic Valve Replacement (TAVR) Surgery
The innovative Edwards Life-Science Sapien Transcatheter Aortic Valve Replacement (TAVR) procedure is now available at Munroe for patients with severe aortic stenosis. In November 2012, Munroe performed its first TAVR. This breakthrough procedure provides patients a viable treatment option who were otherwise unable to withstand conventional surgery due to age or serious medical conditions.
Aortic valves, which regulate blood flow from the heart into the aorta, are susceptible to stenosis (failure to open and insufficiency or blood to flow in the wrong direction, back into the heart). A collaborative team of cardiothoracic surgeons, interventional cardiologists and a cardiac anesthesiologist perform this minimally invasive heart valve replacement surgery together in Munroe's new Hybrid Operating Room. This procedure, shown in the video below, is accomplished through the transapical approach where a small incision is made between the ribs of the left and lower chest to provide direct access into the heart and across the diseased valve.
In contrast to the standard aortic valve replacement, this new approach allows for:
- Smaller incision.
- Faster procedure.
- Shorter recovery time.
- Less tissue damage.
Approximately 300,000 Americans suffer from severe aortic stenosis. Without surgical intervention, Critical aortic stenosis results in a death rate of approximately 50 percent in the first two to three years after diagnosis. At least 30 percent of these patients are unable to undergo surgery for replacement of the aortic valve because of advanced age, heart failure, or the presence of multiple coexisting conditions. The TAVR procedure helps patients with aortic stenosis who, prior to this procedure, were unable to seek surgical treatment. This revolutionary heart valve surgery has already helped many patients with aortic stenosis return to the things they enjoy in life. If you have been diagnosed with aortic stenosis, talk to your physician about the TAVR procedure.